Finance

Lists
FULC:NASDAQ
Fulcrum Therapeutics Inc
$3.80
-1.04%
(-0.040) 1D
$3.80
0.00% (0.00)
Pre-market
Closed: Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FULC...
Open
$3.82
High
$3.84
Low
$3.79
Mkt. cap
289.93M
Avg. vol.
1.71M
Volume
102.00
52-wk high
$15.74
52-wk low
$2.91
EPS
-$1.21
Beta
2.59
Shares outstanding
76.30M
No. of employees
9
Open
$3.82
High
$3.84
Low
$3.79
Mkt. cap
289.93M
Avg. vol.
1.71M
Volume
102.00
52-wk high
$15.74
52-wk low
$2.91
EPS
-$1.21
Beta
2.59
Shares outstanding
76.30M
No. of employees
9
News stories
From web sources and news partners
About Fulcrum Therapeutics Inc
CEO-
Employees9
Founded2015
Headquarters-
SectorPharmaceutical industry
Websitefulcrumtx.com
Analyst ratings
Based on 2 analysts giving stock ratings to FULC in the past 3 months
Sell
Buy
0
Hold
1
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for FULC in the last 3 months.
Highest
Current $3.80
$3.00 (-21.05%)
Average
$3.00 (-21.05%)
Lowest
$3.00 (-21.05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gregory Renza
Truist Financial
Hold
Maintained
-
-
08/18/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
$3.00
-21.1%
08/07/2026
Anupam Rama
J.P. Morgan
Sell
Downgraded
-
-
06/02/2026
Andrew Fein
H.C. Wainwright
Hold
Downgraded
$3.00
-21.1%
06/02/2026
Joseph Schwartz
Leerink Partners
Hold
Downgraded
$4.00
+5.3%
06/02/2026
Edward Tenthoff
Piper Sandler
Sell
Downgraded
$3.00
-21.1%
06/02/2026
James Condulis
Stifel Nicolaus
Hold
Downgraded
$3.00
-21.1%
06/02/2026
Luca Issi
RBC Capital
Hold
Maintained
$4.00
+5.3%
06/02/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$15.00
+294.7%
04/28/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$24.00
+531.6%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
14.30M
15.42M
-
-
Cost of revenue
14.30M
15.42M
-
-
Research and development expenses
-
-
14.08M
12.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.56M
7.28M
8.10M
7.46M
Operating expense
7.56M
7.28M
22.19M
19.91M
Total operating expenses
21.86M
22.69M
22.19M
19.91M
Operating income
-21.86M
-22.69M
-22.19M
-19.91M
Other non operating income
-
-
-
-
EBT including unusual items
-19.60M
-20.33M
-18.89M
-26.18M
EBT excluding unusual items
-19.60M
-20.33M
-18.89M
-16.78M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.60M
-20.33M
-18.89M
-26.18M
Net profit margin
-
-
-
-
Earnings per share
-0.31
-0.31
-0.25
-0.22
Interest and investment income
2.26M
2.36M
3.30M
3.13M
Interest expense
-
-
-
-
Net interest expenses
2.26M
2.36M
3.30M
3.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.51M
-22.35M
-21.85M
-19.69M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps